DIE BEDEUTUNG VERAENDERTER MONOAMIN OXIDASE BEI PATIENTEN MIT PSYCHIATRISCHEN ERKRANKUNGEN = L'IMPORTANCE DE LA MODIFICATION DE LA MONOAMINE OXYDASE CHEZ LES PATIENTS AVEC MALADIES PSYCHIATRIQUESDEMISCH L.1982; NERVENARZT; ISSN 0028-2804; DEU; DA. 1982; VOL. 53; NO 8; PP. 455-460; BIBL. 20 REF.Article

STIMULATION OF HUMAN PROLACTIN SECRETION BY MESCALINEDEMISCH L; NEUBAUER M.1979; PSYCHOPHARMACOLOGY; DEU; DA. 1979; VOL. 64; NO 3; PP. 361-363; BIBL. 20 REF.Article

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM. V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXY-BENZOIC ACID = LE METABOLISME OXYDATIF DE LA MESCALINE DANS LE SYSTEME NERVEUX CENTRAL. V. LA DEAMINATION IN VITRO DE LA MESCALINE EN ACIDE TRIMETHOXY-3,4,5 BENZOIQUEDEMISCH L; SEILER N.1975; BIOCHEM. PHARMACOL.; G.B.; DA. 1975; VOL. 24; NO 5; PP. 575-580; BIBL. 36REF.Article

A ROUTINE ASSAY PROCEDURE FOR MONOAMINE OXIDASE AND ITS APPLICATION TO HUMAN BLOOD PLATELETS.DEMISCH L; BOCHNIK HJ; SEILER N et al.1976; CLIN. CHIM. ACTA; PAYS-BAS; DA. 1976; VOL. 70; NO 3; PP. 357-369; BIBL. 36 REF.Article

FACTORS ALTERING PLATELET MONOAMINE OXIDASE: THE INFLUENCE OF ORAL GLUCOSE INTAKEDEMISCH L; DEMISCH K; SEILER N et al.1979; METABOLISM; USA; DA. 1979; VOL. 28; NO 2; PP. 144-150; BIBL. 51 REF.Article

3,4,5-TRIMETHOXYBENZOIC ACID, A NEW MESCALINE METABOLITE IN HUMANS.DEMISCH L; KACZMARCZYK P; SEILER N et al.1978; DRUG. METABOL. DISPOSIT.; USA; DA. 1978; VOL. 6; NO 5; PP. 507-509; BIBL. 11 REF.Article

Changes in flash but not pattern evoked cortical potentials after subchronic application of a monoamine oxidase (MAO) type a inhibitor in manBERDJIS, H; DEMISCH, L.Electroencephalography and clinical neurophysiology. 1985, Vol 62, Num 1, pp 77-80, issn 0013-4694Article

CORRELATION OF PLATELET MAO ACTIVITY WITH INTROVERSION: A STUDY ON A GERMAN RURAL POPULATIONDEMISCH L; GEORGI K; PATZKE B et al.1982; PSYCHIATRY RES.; ISSN 0165-1781; NLD; DA. 1982; VOL. 6; NO 3; PP. 303-311; BIBL. 24 REF.Article

SUBSTRATE-TYPIC CHANGES OF PLATELET MONOAMINE OXIDASE ACTIVITY IN SUB-TYPES OF SCHIZOPHRENIA.DEMISCH L; VON DER MUHLEN H; BOCHNIK HJ et al.1977; ARCH. PSYCHIATR. NERVENKRANKH.; DTSCH.; DA. 1977; VOL. 224; NO 4; PP. 319-329; BIBL. 3 P.Article

LOW PLATELET MAO ACTIVITY IN PSYCHIATRIC PATIENTS AND PLASMA FACTORS: NO EVIDENCE FOR INHIBITORY INFLUENCES ON MAO IN THE CIRCULATING PLATELET POPULATIONDEMISCH L; GEBHART P; KACZMARCZYK P et al.1981; BIOL. PSYCHIATRY; ISSN 0006-3223; USA; DA. 1981; VOL. 16; NO 1; PP. 21-33; BIBL. 2 P.Article

Treatment of severe chronic insomnia with L-tryptophan: results of a double-blind cross-over studyDEMISCH, K; BAUER, J; GEORGI, K et al.Pharmacopsychiatry. 1987, Vol 20, Num 6, pp 242-244, issn 0176-3679Article

Plasma homovanillic acid concentrations in catatoniaNORTHOFF, G; DEMISCH, L; WENKE, J et al.Biological psychiatry (1969). 1996, Vol 39, Num 6, pp 436-443, issn 0006-3223Article

Light exposure patterns in schizophreniaGERBALDO, H; DEMISCH, L; CARDINALI, D. P et al.Acta psychiatrica Scandinavica. 1992, Vol 85, Num 1, pp 94-95, issn 0001-690XArticle

The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamineDEMISCH, K; DEMISCH, L; NICKELSEN, T et al.Journal of neural transmission. 1987, Vol 68, Num 3-4, pp 257-270, issn 0300-9564Article

Results of an open clinical trial of brofaromine (CGP11305A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depressionSTEIGER, A; HOLSBOER, F; GERKEN, A et al.Pharmacopsychiatry. 1987, Vol 20, Num 6, pp 262-269, issn 0176-3679Article

Dose response and concentration response relationship of apomorphine in patients with parkinson's disease and end-of-dose akinesiaHARDER, S; BAAS, H; DEMISCH, L et al.International journal of clinical pharmacology and therapeutics. 1998, Vol 36, Num 7, pp 355-361, issn 0946-1965Article

Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychosesDEMISCH, L; HEINZ, K; GERBALDO, H et al.Prostaglandins, leukotrienes and essential fatty acids. 1992, Vol 46, Num 1, pp 47-52, issn 0952-3278Article

Catatonia : short-term response to lorazepam and dopaminergic metabolismNORTHOFF, G; WENKE, J; DEMISCH, L et al.Psychopharmacologia. 1995, Vol 122, Num 2, pp 182-186, issn 0033-3158Article

Circadian profiles of melatonin in melancholic depressed patients and healthy subjects in relation to cortisol secretion and sleepVODERHOLZER, U; LAAKMANN, G; BECKER, U et al.Psychiatry research. 1997, Vol 71, Num 3, pp 151-161, issn 0165-1781Article

Incorporation of ¹⁴C-arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disordersDEMISCH, L; GERBALDO, H; GEBHART, P et al.Psychiatry research. 1987, Vol 22, Num 4, pp 275-282, issn 0165-1781Article

Comparison of the ACTH suppression test and dexamethasone suppression test in depressed patientsDEMISCH, K; DEMISCH, L; BOCHNIK, H.-J et al.The American journal of psychiatry. 1983, Vol 140, Num 11, pp 1511-1512, issn 0002-953XArticle

Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels : effects of tryptophan depletion in healthy subjectsDIERKS, T; BARTA, S; DEMISCH, L et al.Psychopharmacologia. 1999, Vol 146, Num 1, pp 101-107, issn 0033-3158Article

Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuationsBAAS, H; HARDER, S; BÜRKLIN, F et al.Clinical neuropharmacology. 1998, Vol 21, Num 2, pp 86-92, issn 0362-5664Article

Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulationHARDER, S; BAAS, H; BERGEMANN, N et al.British journal of clinical pharmacology. 1995, Vol 39, Num 1, pp 39-44, issn 0306-5251Conference Paper

Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and β₂-microglobulin levels in CSF and serum of patients with relapsing-remitting of chronic-progressive multiple sclerosisOTT, M; DEMISCH, L; ENGELHARDT, W et al.Journal of neurology. 1993, Vol 241, Num 2, pp 108-114, issn 0340-5354Article